


I hereby certify that this correspondence (and any paper or fee referred to as being transmitted herewith) via first class mail in an envelope, addressed to the COMMISSIONER FOR PATENTS, ALEXANDRIA, VIRGINIA 22313, on



November 18, 2003  
(Date)

Traci Higgins 11/18/03  
(Signature and Date)

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Patent Application of:

Han et al.

Serial No. :	10/654,770	Art Unit :	Unassigned
Filed :	August 21, 2003	Examiner :	Unassigned
Title :	APPARATUS AND METHOD FOR MEASURING A WEIGHT LOAD EXERTED BY A LEG OF A LAB ANIMAL OR A HUMAN; BEING		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. 1.97-1.99, applicants respectfully request that the following references be made of record in the above-identified application:

<b>United States Patents</b>	<b>Issued</b>	<b>Inventor(s)</b>
4,427,083	January 24, 1984	Muddle
4,804,052	February 14, 1989	Griffen
5,724,267	March 3, 1998	Richards
5,734,128	March 31, 1998	Gades et al.
6,629,056 B2	September 30, 2003	Han et al.

**Other Documents**

Larsen et al., "Reduction in Locomotor Activity of Arthritic Rats as Parameter for Chronic Pain : Effect of Morphine, Acetylsalicylic Acid and Citalopram," *Acta Pharmacol. Et Toxicol.*, 57:345-351 (1985).

Cain et al., "Pain-Related Disability and Effects of Chronic Morphine in the Adjuvant-Induced Arthritis Model of Chronic Pain," *Physiology & Behavior*, **62**(1):199-205 (1997).

Hallas et al., "Establishment of Behavioral Parameters For The Evaluation of Osteopathic Treatment Principles in a Rat Model of Arthritis," *JAOA*, **97**(4):207-214 (1997).

Sluka et al., "Differential Effects of N-Methyl-D-Aspartate (NMDA) and non-NMDA Receptor Antagonists on Spinal Release of Amino Acids After Development of Acute Arthritis In Rats," *Brain Research*, **664**:77-84 (1994).

Lawand et al., "Nicotinic Cholinergic Receptors : Potential Targets for Inflammatory Pain Relief," *Pain*, **80**:291-299, (1999).

Lu et al., "Gabapentin Attenuates Nociceptive Behaviors in an Acute Arthritis Model In Rats," *The Journal of Pharmacology and Experimental Therapeutics*, **290**(1):214-219 (1999).

Okuda et al., "Arthritis Induced in Cat by Sodium Urate : A Possible Animal Model for Tonic Pain," *Pain*, **18**:287-297 (1984).

Clarke, K.A., "Differential Fore- and Hindpaw Force Transmission in the Walking Rat," *Physiology & Behavior*, **58**(3):415-419 (1995).

Clarke et al., "Gait Analysis in a Rat Model of Osteoarthritis," *Physiology & Behavior*, **62**(5):951-954 (1997).

Schott et al., "Weight Bearing as an Objective Measure of Arthritic Pain in the Rat," *Journal of Pharmacological and Toxicological Methods*, **31**(2):79-83 (1994).

Copies of the aforementioned publications are submitted herewith along with a completed form PTO-1449. The references are listed on form PTO-1449.

Consideration of this Information Disclosure Statement is respectfully requested, since the information provided herein may be material to the patentability of the subject application as defined in 37 C.F.R. §1.56. The submission of references with this Information Disclosure Statement should not be construed by the Examiner that a comprehensive search through the prior art was conducted; it is requested that the Examiner make such a comprehensive search.

The above citations do not constitute an admission that the references are relevant or material to the claims; they are cited only as constituting the closest art of which applicant is aware. As such, it is respectfully submitted that the Claims presented for examination define patentable subject matter thereover. Favorable consideration on the merits is respectfully requested.

***Correspondence and Fees***

Please address all correspondence to Intellectual Property Docket Administrator, Gibbons, Del Deo, Dolan, Griffinger & Vecchione, One Riverfront Plaza, Newark, NJ 07102-5497. Telephone calls should be made to Livia Boyadjian at (973) 596-4825 and fax communications should be sent directly to her at (973) 639-8350.

Should any fees be required, please charge the required fee to Deposit Account No. 03-3839.

Thank you for your consideration.

Date: November 18, 2003



---

Livia Boyadjian  
Attorney for Applicant  
Registration No. 34,781

Gibbons, Del Deo, Dolan,  
Griffinger & Vecchione  
One Riverfront Plaza  
Newark, New Jersey 07102



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
It is illegal to respond to a collection of information unless it contains a valid OMB

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449A/PTO**

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 1 of 2

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Application Number	10/654,770
		Filing Date	August 21, 2003
		First Named Inventor	HAN, Hee-Chul
		Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	1	of	2
		Attorney Docket Number	

U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Initials*		Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines. Where Relevant Passages or Relevant Figures Appear	T

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

English language translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449B/PTO**

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Substitute for form 1449B/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Application Number	10/654,770
		Filing Date	August 21, 2003
		First Named Inventor	HAN, Hee-Chul
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	2	of	2
		Attorney Docket Number	102084-39581 CIP

#### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		<p>Larsen et al., "Reduction in Locomotor Activity of Arthritic Rats as Parameter for Chronic Pain: Effect of Morphine, Acetylsalicylic Acid and Citalopram," <i>Acta Pharmacol. Et Toxicol.</i>, 57:345-351 (1985).</p> <p>Cain et al., "Pain-Related Disability and Effects of Chronic Morphine in the Adjuvant-Induced Arthritis Model of Chronic Pain," <i>Physiology &amp; Behavior</i>, 62(1):199-205 (1997).</p> <p>Hallas et al., "Establishment of Behavioral Parameters for the Evaluation of Osteopathic Treatment Principles in a Rat Model of Arthritis," <i>JAOA</i>, 97(4):207-214 (1997).</p> <p>Sluka et al. "Differential Effects of N-Methyl-D-Aspartate (NMDA) and non-NMDA Receptor Antagonists on Spinal Release of Amino Acids After Development of Acute Arthritis in Rats," <i>Brain Research</i>, 664:77-84 (1994).</p> <p>Lawand et al., "Nicotinic Cholinergic Receptors: Potential Targets for Inflammatory Pain Relief," <i>Pain</i>, 80:291-299, (1999).</p> <p>Lu et al., "Gabapentin Attenuates Nociceptive Behaviors in a Acute Arthritis Model in Rats," <i>The Journal of Pharmacology and Experimental Therapeutics</i>, 290(1):214-219 (1999).</p> <p>Okuda et al., "Arthritis Induced in Cat by Sodium Urate: A possible Animal Model For Tonic Pain," <i>Pain</i>, 18:287-297 (1984).</p> <p>Clarke, K.A., "Differential Fore-and Hindpaw Force Transmission in the Walking Rat," <i>Physiology &amp; Behavior</i>, 58(3): 415-419 (1995).</p> <p>Clarke et al., "Gait Analysis in a Rat Model of Osteoarthritis," <i>Physiology &amp; Behavior</i>, 62(5):951-954 (1997).</p> <p>Schott et al., "Weight Bearing as an Objective Measure of Arthritic Pain in the Rat," <i>Journal of Pharmacological and Toxicological Methods</i>, 31(2):79-83 (1994).</p>	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.